TauRx Therapeutics Ltd
11
0
0
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
18.2%
2 terminated/withdrawn out of 11 trials
80.0%
-6.5% vs industry average
45%
5 trials in Phase 3/4
38%
3 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment
Role: lead
TRx0237 for the Treatment of Early and Mild-Moderate Alzheimer's Disease
Role: lead
Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)
Role: lead
Open Label Study of TRx0014 in Alzheimer's Disease
Role: lead
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
Role: lead
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Role: lead
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
Role: lead
Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease
Role: lead
Multiple Dose Study of TRx0037
Role: lead
Comparative Bioavailability in Healthy Elderly Volunteers
Role: lead
TRx0014 in Patients With Mild or Moderate Alzheimer's Disease
Role: lead
All 11 trials loaded